1. Envita's AAIT - a Powerful Immunotherapy
for Cancer
AAIT is an acronym for autologous adoptive immune therapy and describes a therapy
conceived from a patient’s blood, which is eventually re-infused during treatment. There
are a plethora of strategies for immunotherapy and just as many treatments that belong
under the heading “autologous adoptive immunotherapy.” That said – not all options
measure up to our standard..
Envita’s immunotherapy, AAIT, involves 4 major cell types including:
• Natural killer cells
• Natural killer T cells
• Cytokine-induced killer cells
• Cytotoxic T lymphocytes
The inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the
strategic focus of Envita’s AAIT immunotherapy serums.
Natural Killer Cells Important in Cancer Prognosis of Cancer
When NK cell numbers and functionality are low, cancer patients are predisposed to
more aggressive tumor growth. And, as disease progresses, such declines are likely to
continue. In both animal and human clinical trials, we have seen that by restoring NK
and NKT function leads to enhanced cellular immune tumor-response and higher
patient survival rates.
Keys to Envita's AAIT Uniqueness
1) Envita's protocol for AAIT is regulated to optimize the expansion of natural killer cells
- the most potent cancer fighting component of the cellular immune system. Most

2. immune therapies do necessarily use natural killer cells, however, those that do only
expand them in sparse numbers with little activation.
2) Envita's AAIT protocol demands only 4-5 weeks to grow these cells, so patients can
expect to experience benefits quickly. Moreover, while other immune therapies
administer approximately 100-200 million cells per treatment, Envita delivers roughly
100 times as many during the course of treatment.
3) Myriads of published research studies demonstrate the effects of adoptive immune
therapy in cancer patients by which Envita has identified and improved upon the most
effective applications. Company protocol eschews the highest-level of procedure for the
expansion and application of cells for each immunotherapy treatment.
4) In contrast to other published immune therapies, Envita's AAIT is the only one that
can be administered as a “stand-alone.” Moreover, it may also be administered in
conjunction with other therapies to enhance the cells’ effects in patients – a huge and
incomparable benefit. Envita's AAIT therapy is not focused solely on expanding cells in
the lab; rather, our intention is to keep them active until reintroduced into the patient’s
body.
5) Envita’s AAIT guarantees far greater tumor kill, or cytotoxicity than that of other
touted cancer cell vaccines / immunotherapy treatments found worldwide. Briefly, this
means Envita’s activated natural killer cells in AAIT deliver shockingly higher tumor
obliteration.
6) In conclusion, the most direct means with which to compare Envita’s proprietary
immunotherapy against the others includes its:
a. Quality - based on cytoxicity (how much tumor the immune system can kill).
Envita’s AAIT immunotherapy consistently delivers “significantly greater tumor
eradication.
b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy
delivers 100 times the cell dosage than all others.
c. Sterility (quality control measures) – Envita AAIT immunotherapy is
guaranteed to be contaminant free.
If you have any inquiries with particular regard to Envita's AAIT immunotherapy, please
consult Envita’s team of physicians and patient educators. This immunotherapy is
utilized at Envita’s international cancer center in Mexico.